Crohn's disease and ulcerative colitis: Occurrence, course and prognosis during the first year of disease in a European population-based inception cohort

Danish Medical Journal

Volumn 61, Issue 1, 2014, Pages

  Burisch, Johan ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CYCLOSPORIN; GLUCOCORTICOID; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; STEROID; ANTIINFLAMMATORY AGENT; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; BIOLOGICAL THERAPY; COHORT ANALYSIS; CROHN DISEASE; DISEASE ACTIVITY; DISEASE ACTIVITY SCORE; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; EASTERN EUROPE; ELECTRONIC MEDICAL RECORD; ENVIRONMENTAL FACTOR; FOLLOW UP; HEALTH ASSESSMENT QUESTIONNAIRE; HEALTH CARE QUALITY; HEALTH CARE UTILIZATION; HOSPITAL COST; HUMAN; INCIDENCE; INFLAMMATORY BOWEL DISEASE; PATIENT EDUCATION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RESIDENTIAL CARE; SHORT FORM 12; SURGICAL RISK; ULCERATIVE COLITIS; WESTERN EUROPE; ADOLESCENT; ADULT; AGED; ECONOMICS; EUROPE; FACTUAL DATABASE; FEMALE; HEALTH CARE COST; INTERNET; MALE; MIDDLE AGED; MULTICENTER STUDY; PROGNOSIS; PROSPECTIVE STUDY; RISK FACTOR; SEVERITY OF ILLNESS INDEX; STATISTICS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS; COLITIS, ULCERATIVE; CROHN DISEASE; DATABASES, FACTUAL; DISEASE PROGRESSION; EUROPE; FEMALE; FOLLOW-UP STUDIES; HEALTH CARE COSTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; INTERNET; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; QUALITY OF HEALTH CARE; QUALITY OF LIFE; RISK FACTORS; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84892469233     PISSN: None     EISSN: 22451919     Source Type: Journal    
DOI: None     Document Type: Article

References (168)

1. Orholm M, Munkholm P, Langholz E, et al. Familial occurrence of inflammatory bowel disease. N Engl J Med 1991;324:84-8.
2. Danese S, Sans M, Fiocchi C. Inflammatory bowel disease: the role of environmental factors. Autoimmun Rev 2004;3:394-400.
3. Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet 2007;369:1627-40.
4. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl 1989;170:2-6.
5. Munkholm P. Crohn's disease-occurrence, course and prognosis. An epidemiologic cohort-study. Dan Med Bull 1997;44:287-302.
6. Langholz E. Ulcerative colitis. An epidemiological study based on a regional inception cohort, with special reference to disease course and prognosis. Dan Med Bull 1999;46:400-15.
7. Langholz E, Munkholm P, Davidsen M, et al. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology 1994;107:3-11.
8. Munkholm P, Langholz E, Davidsen M, et al. Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol 1995;30:699-706.
9. Dignass A, Lindsay JO, Sturm A, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management. J Crohns Colitis 2012;6:991-1030.
10. Dignass A, Assche G Van, Lindsay JO, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. J Crohns Colitis 2010;4:28-62.
11. Vind I, Riis L, Jess T, et al. Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003-2005: a population-based study from the Danish Crohn colitis database. Am J Gastroenterol 2006;101:1274-82.
12. Moum B, Vatn MH, Ekbom A, et al. Incidence of ulcerative colitis and indeterminate colitis in four counties of southeastern Norway, 1990-93. A prospective population-based study. The Inflammatory Bowel South-Eastern Norway (IBSEN) Study Group of Gastroenterologists. Scand J Gastroenterol 1996;31:362-6.
13. Moum B, Vatn MH, Ekbom A, et al. Incidence of Crohn's disease in four counties in southeastern Norway, 1990-93. A prospective population-based study. The Inflammatory Bowel South-Eastern Norway (IBSEN) Study Group of Gastroenterologists. Scand J Gastroenterol 1996;31:355-61.
14. Ekbom A, Helmick C, Zack M, et al. The epidemiology of inflammatory bowel disease: a large, population-based study in Sweden. Gastroenterology 1991;100:350-8.
15. Björnsson S, Jóhannsson JH. Inflammatory bowel disease in Iceland, 1990-1994: a prospective, nationwide, epidemiological study. Eur J Gastroenterol Hepatol 2000;12:31-8.
16. Rubin GP, Hungina P, Kelly PJ, et al. Inflammatory bowel disease: epidemiology and management in an English general practice population. Aliment Pharmacol Ther 2000;14:1553-9.
17. Gunesh S, Thomas G a O, Williams GT, et al. The incidence of Crohn's disease in Cardiff over the last 75 years: an update for 1996-2005. Aliment Pharmacol Ther 2008;27:211-9.
18. Bernstein CN, Wajda A, Svenson LW, et al. The epidemiology of inflammatory bowel disease in Canada: a population-based study. Am J Gastroenterol 2006;101:1559-68.
19. Loftus CG, Loftus E V, Harmsen WS, et al. Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000. Inflamm Bowel Dis 2007;13:254-61.
20. Burisch J, Jess T, Martinato M, et al. The burden of inflammatory bowel disease in Europe. J Crohns Colitis 2013;7:322-337.
21. Lakatos L, Kiss LS, David G, et al. Incidence, disease phenotype at diagnosis, and early disease course in inflammatory bowel diseases in Western Hungary, 2002-2006. Inflamm Bowel Dis 2011;17:2558-65.
22. Sincić BM, Vucelić B, Persić M, et al. Incidence of inflammatory bowel disease in Primorsko-goranska County, Croatia, 2000-2004: A prospective population-based study. Scand J Gastroenterol 2006;41:437-44.
23. Burisch J, Munkholm P. Inflammatory bowel disease epidemiology. Curr Opin Gastroenterol 2013;29:357-62.
24. Frangos CC, Frangos CC. Inflammatory bowel disease: reviewing an old study under a new perspective. Gut 2007;56:1638-9.
25. Lakatos L, Lakatos PL. Management of inflammatory bowel diseases in Eastern Europe. Postgrad Med J 2006;82:270-3.
26. Lakatos P-L. Recent trends in the epidemiology of inflammatory bowel diseases: up or down? World J Gastroenterol 2006;12:6102-8.
27. OCEBM Levels of Evidence Working Group. The Oxford 2011 Levels of Evidence. Oxford Cent Evidence-Based Med 2011;1. Available at: http://www.cebm.net/index.aspx?o=5653 [Accessed July 31, 2013].
28. Höj L, Jensen PB, Bonnevie O, et al. An epidemiological study of regional enteritis and acute ileitis in Copenhagen County. Scand J Gastroenterol 1973;8:381-4.
29. Bonnevie O, Riis P, Anthonisen P. An epidemiological study of ulcerative colitis in Copenhagen County. Scand J Gastroenterol 1968;3:432-8.
30. Danish Crohn Colitis Database. Homepage. Available at: www.dccd-ibd.dk [Accessed January 1, 2008].
31. Stockbrügger R, Russel M, Blankenstein M van, et al. EC-IBD: a European effort in inflammatory bowel disease. Eur J Intern Med 2000;11:187-190.
32. Shivananda S, Lennard-Jones J, Logan R, et al. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Gut 1996;39:690-7.
33. Burisch J, Munkholm P. Is there an East-West incidence gradient in IBD in Europe caused by environmental factors and vitamin D level? ECCO News 2009:10-11.
34. Burisch J, Cukovic-Cavka S, Kaimakliotis I, et al. Construction and validation of a web-based epidemiological database for inflammatory bowel diseases in Europe An EpiCom study. J Crohns Colitis 2011;5:342-9.
35. EpiCom Group. EpiCom Project Website. Available at: www.epicom-ecco.eu [Accessed January 1, 2013].
36. HD-Support LLC. Company website. Available at: www.hd-support.dk/ [Accessed January 1, 2013].
37. The Danish Data Protection Agency. Hompage. Available at: www.datatilsynet.dk/english/ [Accessed July 19, 2013].
38. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005;19 Suppl A:5-36.
39. Riis L, Munkholm P, Binder V, et al. Intra-and interobserver variation in the use of the Vienna classification of Crohn's disease. Inflamm Bowel Dis 2005;11:657-61.
40. Krishnaprasad K, Andrews JM, Lawrance IC, et al. Inter-observer agreement for Crohn's disease sub-phenotypes using the Montreal Classification: How good are we? A multi-centre Australasian study. J Crohns Colitis 2012;6:287-93.
41. World Health Organisation. International Statistical Classification of Diseases and Related Health Problems 10th Revision. 2010. Available at: http://apps.who.int/classifications/icd10/browse/2010/en [Accessed May 1, 2013].
42. Chande N, Tsoulis DJ, MacDonald JK. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane database Syst Rev 2013;4:CD000545.
43. Walmsley RS, Ayres RC, Pounder RE, et al. A simple clinical colitis activity index. Gut 1998;43:29-32.
44. Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet 1980;1:514.
45. Higgins PDR, Schwartz M, Mapili J, et al. Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis. Gut 2005;54:782-8.
46. Best WR. Predicting the Crohn's disease activity index from the Harvey-Bradshaw Index. Inflamm Bowel Dis 2006;12:304-10.
47. Irvine EJ, Zhou Q, Thompson AK. The Short Inflammatory Bowel Disease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohn's Relapse Prevention Trial. Am J Gastroenterol 1996;91:1571-8.
48. Ware JE, Kosinski M, Turner-Bowker DM, et al. How to score version 2 of the SF-12 Health Survey. QualityMetric Incorporated; 2002:1-267.
49. Ware JE, Gandek B, Kosinski M, et al. The equivalence of SF-36 summary health scores estimated using standard and country-specific algorithms in 10 countries: results from the IQOLA Project. International Quality of Life Assessment. J Clin Epidemiol 1998;51:1167-70.
50. Gandek B, Ware JE, Aaronson NK, et al. Cross-validation of item selection and scoring for the SF-12 Health Survey in nine countries: results from the IQOLA Project. International Quality of Life Assessment. J Clin Epidemiol 1998;51:1171-8.
51. Halfvarson J, Jess T, Magnuson A, et al. Environmental factors in inflammatory bowel disease: a co-twin control study of a Swedish-Danish twin population. Inflamm Bowel Dis 2006;12:925-33.
52. Vind I, Riis L, Jespersgaard C, et al. Genetic and environmental factors as predictors of disease severity and extent at time of diagnosis in an inception cohort of inflammatory bowel disease, Copenhagen County and City 2003-2005. J Crohns Colitis 2008;2:162-9.
53. Jakobsen C, Paerregaard A, Munkholm P, et al. Environmental factors and risk of developing paediatric inflammatory bowel disease-a population based study 2007-2009. J Crohns Colitis 2013;7:79-88.
54. Hansen TS, Jess T, Vind I, et al. Environmental factors in inflammatory bowel disease: a case-control study based on a Danish inception cohort. J Crohns Colitis 2011;5:577-84.
55. Elkjaer M, Moser G, Reinisch W, et al. IBD patients need in health quality of care ECCO consensus. J Crohns Colitis 2008;2:181-8.
56. The Danish Ministry of Health. Charges 2013. Available at: http://www.ssi.dk/Sundhedsdataogit/Sundhedsoekonomi/Takster/Takster 2013.aspx [Accessed May 1, 2013].
57. Pharmacy of the Capital Region of Denmark. Prices for medicine 2013. Available at: http://www.apoteket-regionh.dk [Accessed April 28, 2013].
58. Danmarks Nationalbank. Danmarks Nationalbank-Statistikbank. 2013. Available at: http://nationalbanken.statistikbank.dk [Accessed July 1, 2013].
59. Wolters FL, Zeijl G van, Sijbrandij J, et al. Internet-based data inclusion in a population-based European collaborative follow-up study of inflammatory bowel disease patients: description of methods used and analysis of factors influencing response rates. World J Gastroenterol 2005;11:7152-8.
60. Ahmad OB, Boschi-pinto C, Lopez AD. Age standardization of rates: a new WHO standard World Health Organization 2001.; 2001:1-14.
61. World Bank. World Development Indicators database. Accessed 9 July 2012. Available at: http://data.worldbank.org/ [Accessed July 9, 2012].
62. Gower-Rousseau C, Vasseur F, Fumery M, et al. Epidemiology of inflammatory bowel diseases: new insights from a French population-based registry (EPIMAD). Dig Liver Dis 2013;45:89-94.
63. Jess T, Riis L, Vind I, et al. Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: a population-based study from Copenhagen, Denmark. Inflamm Bowel Dis 2007;13:481-9.
64. Vucelić B, Korać B, Sentić M, et al. Epidemiology of Crohn's disease in Zagreb, Yugoslavia: a ten-year prospective study. Int J Epidemiol 1991;20:216-20.
65. Vucelić B, Korać B, Sentić M, et al. Ulcerative colitis in Zagreb, Yugoslavia: incidence and prevalence 1980-1989. Int J Epidemiol 1991;20:1043-7.
66. Jacobsen BA, Fallingborg J, Rasmussen HH, et al. Increase in incidence and prevalence of inflammatory bowel disease in northern Denmark: a population-based study, 1978-2002. Eur J Gastroenterol Hepatol 2006;18:601-6.
67. Salupere R. Inflammatory bowel disease in Estonia: a prospective epidemiologic study 1993-1998. World J Gastroenterol 2001;7:387-8.
68. Róin F, Róin J. Inflammatory bowel disease of the Faroe Islands, 1981-1988. A prospective epidemiologic study: primary report. Scand J Gastroenterol Suppl 1989;170:44-6.
69. Manninen P, Karvonen A-L, Huhtala H, et al. The epidemiology of inflammatory bowel diseases in Finland. Scand J Gastroenterol 2010;45:1063-7.
70. Tragnone A, Corrao G, Miglio F, et al. Incidence of inflammatory bowel disease in Italy: a nationwide population-based study. Gruppo Italiano per lo Studio del Colon e del Retto (GISC). Int J Epidemiol 1996;25:1044-52.
71. Trallori G, Palli D, Saieva C, et al. A population-based study of inflammatory bowel disease in Florence over 15 years (1978-92). Scand J Gastroenterol 1996;31:892-9.
72. Gheorghe C, Pascu O, Gheorghe L, et al. Epidemiology of inflammatory bowel disease in adults who refer to gastroenterology care in Romania: a multicentre study. Eur J Gastroenterol Hepatol 2004;16:1153-9.
73. Burisch J, Pedersen N, Cukovic-Cavka S, et al. East-West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort. Gut 2013:in press.
74. Nielsen KR, Jacobsen S, Olsen K, et al. P637 Incidence and clinical characteristics of inflammatory bowel disease in the Faroe Islands during 2005-2009. J Crohns Colitis 2013;7:S266.
75. Loftus E V. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology 2004;126:1504-17.
76. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012;142:46-54.
77. Ng SC, Bernstein CN, Vatn MH, et al. Geographical variability and environmental risk factors in inflammatory bowel disease. Gut 2013;62:630-49.
78. Hou JK, Abraham B, El-Serag H. Dietary intake and risk of developing inflammatory bowel disease: a systematic review of the literature. Am J Gastroenterol 2011;106:563-73.
79. Burisch J, Pedersen N, Cukovic-Cavka S. Environmental factors in a population-based inception cohort of inflammatory bowel disease patients in Europe-An ECCO-EpiCom study. J Crohns Colitis 2013:in press.
80. Ananthakrishnan AN, Khalili H, Konijeti GG, et al. A Prospective Study of Long-term Intake of Dietary Fiber and Risk of Crohn's Disease and Ulcerative Colitis. Gastroenterology 2013;145:970-7.
81. Amre DK, D'Souza S, Morgan K, et al. Imbalances in dietary consumption of fatty acids, vegetables, and fruits are associated with risk for Crohn's disease in children. Am J Gastroenterol 2007;102:2016-25.
82. Reif S, Klein I, Lubin F, et al. Pre-illness dietary factors in inflammatory bowel disease. Gut 1997;40:754-60.
83. Russel MG, Engels LG, Muris JW, et al. Modern life' in the epidemiology of inflammatory bowel disease: a case-control study with special emphasis on nutritional factors. Eur J Gastroenterol Hepatol 1998;10:243-9.
84. Persson PG, Ahlbom A, Hellers G. Diet and inflammatory bowel disease: a case-control study. Epidemiology 1992;3:47-52.
85. Thornton JR, Emmett PM, Heaton KW. Diet and Crohn's disease: characteristics of the pre-illness diet. BMJ 1979;2:762-4.
86. Gent AE, Hellier MD, Grace RH, et al. Inflammatory bowel disease and domestic hygiene in infancy. Lancet 1994;343:766-7.
87. Duggan AE, Usmani I, Neal KR, et al. Appendicectomy, childhood hygiene, Helicobacter pylori status, and risk of inflammatory bowel disease: a case control study. Gut 1998;43:494-8.
88. Wurzelmann JI, Lyles CM, Sandler RS. Childhood infections and the risk of inflammatory bowel disease. Dig Dis Sci 1994;39:555-60.
89. Romberg-Camps MJL, Hesselink-van de Kruijs MAM, Schouten LJ, et al. Inflammatory Bowel Disease in South Limburg (the Netherlands) 1991-2002: Incidence, diagnostic delay, and seasonal variations in onset of symptoms. J Crohns Colitis 2009;3:115-24.
90. Mahid SS, Minor KS, Soto RE, et al. Smoking and inflammatory bowel disease: a meta-analysis. Mayo Clin Proc 2006;81:1462-71.
91. Cornish J a, Tan E, Simillis C, et al. The risk of oral contraceptives in the etiology of inflammatory bowel disease: a meta-analysis. Am J Gastroenterol 2008;103:2394-400.
92. Cosnes J, Carbonnel F, Carrat F, et al. Oral contraceptive use and the clinical course of Crohn's disease: a prospective cohort study. Gut 1999;45:218-22.
93. Timmer A, Sutherland LR, Martin F. Oral contraceptive use and smoking are risk factors for relapse in Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group. Gastroenterology 1998;114:1143-50.
94. Vind I. Genetic, Serological, and Environmental Factors in Inflammatory Bowel Disease-A Danish Inception Cohort. Dan Med J 2006:1-95.
95. Loftus E V, Silverstein MD, Sandborn WJ, et al. Crohn's disease in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gastroenterology 1998;114:1161-8.
96. Loftus E V, Silverstein MD, Sandborn WJ, et al. Ulcerative colitis in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gut 2000;46:336-43.
97. Lennard-Jones JE, Shivananda S. Clinical uniformity of inflammatory bowel disease a presentation and during the first year of disease in the north and south of Europe. EC-IBD Study Group. Eur J Gastroenterol Hepatol 1997;9:353-9.
98. Thomas GA, Rhodes J, Green JT. Inflammatory bowel disease and smoking-a review. Am J Gastroenterol 1998;93:144-9.
99. Dignass A, Eliakim R, Magro F, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis 2012;6:965-90.
100. Assche G Van, Dignass A, Panes J, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. J Crohns Colitis 2010;4:7-27.
101. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2010;105:501-23; quiz 524.
102. Lichtenstein GR, Hanauer SB, Sandborn WJ. Management of Crohn's disease in adults. Am J Gastroenterol 2009;104:465-83; quiz 464, 484.
103. Mowat C, Cole A, Windsor A, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut 2011;60:571-607.
104. Turner D, Levine A, Escher JC, et al. Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence-based consensus guidelines. J Pediatr Gastroenterol Nutr 2012;55:340-61.
105. IBD Working Group of the European Society for Paediatric Gastroenterology Hepatology and Nutrition. Inflammatory bowel disease in children and adolescents: recommendations for diagnosis-the Porto criteria. J Pediatr Gastroenterol Nutr 2005;41:1-7.
106. Politi P, Bodini P, Mortilla MG, et al. Communication of information to patients with inflammatory bowel disease: A European Collaborative Study in a multinational prospective inception cohort. J Crohns Colitis 2008;2:226-32.
107. Solberg IC, Vatn MH, Høie O, et al. Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol 2007;5:1430-8.
108. Solberg IC, Lygren I, Jahnsen J, et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol 2009;44:431-40.
109. Witte J, Shivananda S, Lennard-Jones JE, et al. Disease outcome in inflammatory bowel disease: mortality, morbidity and therapeutic management of a 796-person inception cohort in the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Scand J Gastroenterol 2000;35:1272-7.
110. Lakatos PL, Golovics PA, David G, et al. Has there been a change in the natural history of Crohn's disease? Surgical rates and medical management in a population-based inception cohort from Western Hungary between 1977-2009. Am J Gastroenterol 2012;107:579-88.
111. D'Haens GR. Top-down therapy for IBD: rationale and requisite evidence. Nat Rev Gastroenterol Hepatol 2010;7:86-92.
112. Neurath MF, Travis SPL. Mucosal healing in inflammatory bowel diseases: a systematic review. Gut 2012;61:1619-35.
113. Ford AC, Kane S V, Khan KJ, et al. Efficacy of 5-aminosalicylates in Crohn's disease: systematic review and meta-analysis. Am J Gastroenterol 2011;106:617-29.
114. Ardizzone S, Maconi G, Sampietro GM, et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology 2004;127:730-40.
115. Duricova D, Pedersen N, Elkjaer M, et al. 5-aminosalicylic acid dependency in Crohn's disease: a Danish Crohn Colitis Database study. J Crohns Colitis 2010;4:575-81.
116. Duricova D, Pedersen N, Lenicek M, et al. The clinical implication of drug dependency in children and adults with inflammatory bowel disease: a review. J Crohns Colitis 2011;5:81-90.
117. Burisch J, Pedersen N, Cukovic-Cavka S, et al. Initial Disease Course and Treatment in an Inflammatory Bowel Disease Inception Cohort in Europe: The ECCO-EpiCom Cohort. Inflamm Bowel Dis 2013:in press.
118. Ramadas A V, Gunesh S, Thomas G a O, et al. Natural history of Crohn's disease in a population-based cohort from Cardiff (1986-2003): a study of changes in medical treatment and surgical resection rates. Gut 2010;59:1200-6.
119. Nguyen GC, Nugent Z, Shaw S, et al. Outcomes of patients with Crohn's disease improved from 1988 to 2008 and were associated with increased specialist care. Gastroenterology 2011;141:90-7.
120. Frolkis AD, Dykeman J, Negrón ME, et al. Risk of Surgery for Inflammatory Bowel Diseases Has Decreased Over Time: A Systematic Review and Meta-analysis of Population-Based Studies. Gastroenterology 2013;145:996-1006.
121. Bernstein CN, Loftus E V, Ng SC, et al. Hospitalisations and surgery in Crohn's disease. Gut 2012;61:622-9.
122. Samuel S, Ingle SB, Dhillon S, et al. Cumulative incidence and risk factors for hospitalization and surgery in a population-based cohort of ulcerative colitis. Inflamm Bowel Dis 2013;19:1858-66.
123. Targownik LE, Singh H, Nugent Z, et al. The epidemiology of colectomy in ulcerative colitis: results from a population-based cohort. Am J Gastroenterol 2012;107:1228-35.
124. Costa J, Magro F, Caldeira D, et al. Infliximab reduces hospitalizations and surgery interventions in patients with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis 2013;19:2098-110.
125. Khan KJ, Dubinsky MC, Ford AC, et al. Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol 2011;106:630-42.
126. Cosnes J, Bourrier A, Laharie D, et al. Early administration of azathioprine vs conventional management of Crohn's disease: a randomized controlled trial. Gastroenterology 2013;145:758-765. e2.
127. Higgins PDR, Schwartz M, Mapili J, et al. Is endoscopy necessary for the measurement of disease activity in ulcerative colitis? Am J Gastroenterol 2005;100:355-61.
128. Hirai F, Matsui T, Aoyagi K, et al. Validity of activity indices in ulcerative colitis: comparison of clinical and endoscopic indices. Dig Endosc 2010;22:39-44.
129. Cellier C, Sahmoud T, Froguel E, et al. Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives. Gut 1994;35:231-5.
130. Modigliani R, Mary JY, Simon JF, et al. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives. Gastroenterology 1990;98:811-8.
131. Thia KT, Sandborn WJ, Harmsen WS, et al. Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort. Gastroenterology 2010;139:1147-55.
132. Langholz E, Munkholm P, Davidsen M, et al. Changes in extent of ulcerative colitis: a study on the course and prognostic factors. Scand J Gastroenterol 1996;31:260-6.
133. Moum B, Ekbom A, Vatn MH, et al. Clinical course during the 1st year after diagnosis in ulcerative colitis and Crohn's disease. Results of a large, prospective population-based study in southeastern Norway, 1990-93. Scand J Gastroenterol 1997;32:1005-12.
134. Bernklev T, Jahnsen J, Lygren I, et al. Health-related quality of life in patients with inflammatory bowel disease measured with the short form-36: psychometric assessments and a comparison with general population norms. Inflamm Bowel Dis 2005;11:909-18.
135. Nordin K, Påhlman L, Larsson K, et al. Health-related quality of life and psychological distress in a population-based sample of Swedish patients with inflammatory bowel disease. Scand J Gastroenterol 2002;37:450-7.
136. Blondel-Kucharski F, Chircop C, Marquis P, et al. Health-related quality of life in Crohn's disease: a prospective longitudinal study in 231 patients. Am J Gastroenterol 2001;96:2915-20.
137. Høivik ML, Bernklev T, Solberg IC, et al. Patients with Crohn's disease experience reduced general health and vitality in the chronic stage: ten-year results from the IBSEN study. J Crohns Colitis 2012;6:441-53.
138. Munkholm P, Pedersen N. Evaluation of quality of life in inflammatory bowel disease. In: Baumgart DC, ed. Crohn's Disease and Ulcerative Colitis: From Epidemiology and Immunobiology to a Rational Diagnostic and Therapeutic Approach. Boston, MA: Springer US; 2012:333-340.
139. Bernklev T, Jahnsen J, Schulz T, et al. Course of disease, drug treatment and health-related quality of life in patients with inflammatory bowel disease 5 years after initial diagnosis. Eur J Gastroenterol Hepatol 2005;17:1037-45.
140. Hoivik ML, Moum B, Solberg IC, et al. Health-related quality of life in patients with ulcerative colitis after a 10-year disease course: results from the IBSEN study. Inflamm Bowel Dis 2011.
141. Bernklev T, Jahnsen J, Aadland E, et al. Health-related quality of life in patients with inflammatory bowel disease five years after the initial diagnosis. Scand J Gastroenterol 2004;39:365-73.
142. Casellas F, Arenas JI, Baudet JS, et al. Impairment of health-related quality of life in patients with inflammatory bowel disease: a Spanish multicenter study. Inflamm Bowel Dis 2005;11:488-96.
143. Canavan C, Abrams KR, Hawthorne B, et al. Long-term prognosis in Crohn's disease: factors that affect quality of life. Aliment Pharmacol Ther 2006;23:377-85.
144. Graff LA, Walker JR, Lix L, et al. The relationship of inflammatory bowel disease type and activity to psychological functioning and quality of life. Clin Gastroenterol Hepatol 2006;4:1491-1501.
145. Casellas F, Barreiro de Acosta M, Iglesias M, et al. Mucosal healing restores normal health and quality of life in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2012;24:762-9.
146. Eijk I van der, Vlachonikolis IG, Munkholm P, et al. The role of quality of care in health-related quality of life in patients with IBD. Inflamm Bowel Dis 2004;10:392-8.
147. Rooy EC de, Toner BB, Maunder RG, et al. Concerns of patients with inflammatory bowel disease: results from a clinical population. Am J Gastroenterol 2001;96:1816-21.
148. Casati J, Toner BB, Rooy EC de, et al. Concerns of patients with inflammatory bowel disease: a review of emerging themes. Dig Dis Sci 2000;45:26-31.
149. Husain A, Triadafilopoulos G. Communicating with patients with inflammatory bowel disease. Inflamm Bowel Dis 2004;10:444-50; discussion 451.
150. Waters BM, Jensen L, Fedorak RN. Effects of formal education for patients with inflammatory bowel disease: a randomized controlled trial. Can J Gastroenterol 2005;19:235-44.
151. Belling R, McLaren S, Woods L. Specialist nursing interventions for inflammatory bowel disease. Cochrane database Syst Rev 2009:CD006597.
152. O'Connor M, Bager P, Duncan J, et al. N-ECCO Consensus statements on the European nursing roles in caring for patients with Crohn's disease or ulcerative colitis. J Crohns Colitis 2013;7:744-64.
153. Bassi A, Dodd S, Williamson P, et al. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut 2004;53:1471-8.
154. Bernstein CN, Papineau N, Zajaczkowski J, et al. Direct hospital costs for patients with inflammatory bowel disease in a Canadian tertiary care university hospital. Am J Gastroenterol 2000;95:677-83.
155. Juan J, Estiarte R, Colomé E, et al. Burden of illness of Crohn's disease in Spain. Dig Liver Dis 2003;35:853-61.
156. Silverstein MD, Loftus E V., Sandborn WJ, et al. Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort. Gastroenterology 1999;117:49-57.
157. Cohen RD, Larson LR, Roth JM, et al. The cost of hospitalization in Crohn's disease. Am J Gastroenterol 2000;95:524-30.
158. Odes S, Vardi H, Friger M, et al. Cost analysis and cost determinants in a European inflammatory bowel disease inception cohort with 10 years of follow-up evaluation. Gastroenterology 2006;131:719-28.
159. Odes S. How expensive is inflammatory bowel disease? A critical analysis. World J Gastroenterol 2008;14:6641-7.
160. Blackhouse G, Assasi N, Xie F, et al. Canadian cost-utility analysis of initiation and maintenance treatment with anti-TNF-α drugs for refractory Crohn's disease. J Crohns Colitis 2012;6:77-85.
161. Sprakes MB, Ford AC, Suares NC, et al. Costs of care for Crohn's disease following the introduction of infliximab: a single-centre UK experience. Aliment Pharmacol Ther 2010;32:1357-63.
162. Valk ME van der, Mangen M-JJ, Leenders M, et al. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study. Gut 2012:in press.
163. Guillemin F, Bombardier C, Beaton D. Cross-cultural adaptation of health-related quality of life measures: literature review and proposed guidelines. J Clin Epidemiol 1993;46:1417-32.
164. Buck D, Jacoby A, Baker GA, et al. Cross-cultural differences in health-related quality of life of people with epilepsy: findings from a European study. Qual Life Res 1999;8:675-85.
165. Levenstein S, Li Z, Almer S, et al. Cross-cultural variation in disease-related concerns among patients with inflammatory bowel disease. Am J Gastroenterol 2001;96:1822-30.
166. Irvine EJ, Feagan BG, Wong CJ. Does self-administration of a quality of life index for inflammatory bowel disease change the results? J Clin Epidemiol 1996;49:1177-85.
167. Eijk I van der, Sixma H, Smeets T, et al. Quality of health care in inflammatory bowel disease: development of a reliable questionnaire (QUOTE-IBD) and first results. Am J Gastroenterol 2001;96:3329-36.
168. Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009;374:1617-25.